<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646955</url>
  </required_header>
  <id_info>
    <org_study_id>DBCG RT Natural Trial</org_study_id>
    <nct_id>NCT03646955</nct_id>
  </id_info>
  <brief_title>Partial Breast Versus no Irradiation for Women With Early Breast Cancer</brief_title>
  <official_title>The DBCG RT Natural Trial: Partial Breast Versus no Irradiation for Women &gt;=60 Years Operated With Breast Conservation for an Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Center for Interventional Research in Radiation Oncology (CIRRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Danish Breast Cancer Cooperative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after&#xD;
      breast conserving surgery for an early breast cancer. Breast cancer is heterogeneous, and&#xD;
      selected patients have a very low gain from RT, whilst they still have risk of acute and late&#xD;
      side effects from RT. This trial will try identify selection criteria for low risk breast&#xD;
      cancer patients who can safely omit adjuvant RT without unacceptable high risk of local&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      International standard of therapy is to provide adjuvant breast radiation therapy (RT) after&#xD;
      breast conserving surgery for an early breast cancer to lower the risk of local and distant&#xD;
      failures. However, breast cancer is a heterogeneous disease, and the gain from RT in selected&#xD;
      low risk patients is low. RT may cause acute and late side effects, and some of these may be&#xD;
      serious to the patient. Therefore, there is a need to tailor RT utilization to the individual&#xD;
      recurrence risk and try identify patients who are unlikely to gain much risk reduction from&#xD;
      RT, because those patients can then omit RT and thereby avoid late effects and&#xD;
      over-treatment. At the present time there is no consensus as to define the selection criteria&#xD;
      for patients who may omit RT.&#xD;
&#xD;
      Based on early results from the randomized DBCG RT PBI trial, external beam 40 Gy/15 fr&#xD;
      partial breast irradiation (PBI) has been standard in Denmark since April 2016 for selected&#xD;
      low risk breast cancer patients. Based on results from the UK IMPORT LOW trial, the 5 yr&#xD;
      local recurrence risk using this technique for PBI is 0.5%, whilst 2% for developing a new&#xD;
      contralateral breast cancer.&#xD;
&#xD;
      This trial will investigate if PBI can safely be omitted in selected low risk breast cancer&#xD;
      patients without causing unacceptable high risk of local failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2033</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Clinically controlled randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Invasive local recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive local recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional nodes recurrence</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive recurrence in regional nodes of the treated breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure</measure>
    <time_frame>10 years</time_frame>
    <description>Invasive recurrence from the breast cancer outside the loco-regional area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>10 years</time_frame>
    <description>Death and cause of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">926</enrollment>
  <condition>Local Neoplasm Recurrence</condition>
  <condition>Distantly Metastatic Malignant Neoplasm</condition>
  <condition>Death</condition>
  <condition>Fibrosis Breast</condition>
  <condition>Depigmentation/Hyperpigmentation of Skin</condition>
  <condition>Telangiectasia</condition>
  <condition>Scar</condition>
  <condition>Pain</condition>
  <condition>PROMs</condition>
  <arm_group>
    <arm_group_label>Partial breast irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No partial breast irradiation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>No partial breast irradiation</intervention_name>
    <description>Omission of radiation therapy</description>
    <arm_group_label>Partial breast irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Female patient &gt;=60 years&#xD;
&#xD;
        Primary tumour characteristics by conventional histopathology&#xD;
&#xD;
          -  unilateral and unifocal non-lobular histology grade 1-2&#xD;
&#xD;
          -  maximum microscopic size &lt;=20mm&#xD;
&#xD;
          -  node negative determined by sentinel node or axillary lymph node dissection&#xD;
&#xD;
          -  estrogen receptor &gt;=10% positive&#xD;
&#xD;
          -  HER2 negative (by IHC and/or in situ hybridization)&#xD;
&#xD;
          -  resection margin &gt;=2 mm for invasive carcinoma and any ductal carcinoma in situ&#xD;
             associated with the cancer&#xD;
&#xD;
        Surgical type is breast conservation&#xD;
&#xD;
        Performance status ECOG 0-2&#xD;
&#xD;
        No evidence of distant metastasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multifocal or multicentric invasive carcinoma or ductal carcinoma in situ&#xD;
&#xD;
          -  evidence of clinical or pathological T4 breast cancer&#xD;
&#xD;
          -  grade 3 malignancy&#xD;
&#xD;
          -  previous breast cancer or DCIS irrespective of disease-free interval&#xD;
&#xD;
          -  previous radiation therapy to the breast or thorax,&#xD;
&#xD;
          -  previous neoplasm within 5 years except carcinoma in situ of the cervix, endometrium&#xD;
             or coli, melanoma in situ.&#xD;
&#xD;
          -  comorbidity precluding the patient from radiation therapy (e.g. cardiovascular or&#xD;
             pulmonary disease, scleroderma, systemic lupus erythematosus).&#xD;
&#xD;
          -  mental/psychiatric disorder which precludes the patient from understanding the&#xD;
             randomization and the follow up.&#xD;
&#xD;
          -  documented hereditary breast cancer or with high genetic risk of breast cancer&#xD;
&#xD;
          -  life expectancy &lt;10 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgitte V Offersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Breast Cancer Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgitte V Offersen, PhD</last_name>
    <phone>+45 28838012</phone>
    <email>bvo@oncology.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ponticia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago de Chile</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Merino Lara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Lörinz, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne M Nielsen, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Kamby, DMSc</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise W Matthiessen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Al-Rawi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mette H Nielsen, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Troels Bechmann, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland HUS</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Petter Eikesdal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bård Mannsåker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kristiansand Hospital</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Unn-Miriam Kasti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Radiumhospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Reinertsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingvil Mjaaland</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tromsø University Hospital</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egil Blix Støre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Lundstedt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Alkner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Lindman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Breast Cancer Cooperative Group</investigator_affiliation>
    <investigator_full_name>Birgitte Offersen</investigator_full_name>
    <investigator_title>Professor, PhD, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Recurrence, Local</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Hyperpigmentation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>When the results from the trial are published, the DBCG RT Committee can decide that the results may be part of a meta-analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>It will only be possible if the DBCG Radiation Therapy Committee decides that it is acceptable</ipd_time_frame>
    <ipd_access_criteria>The DBCG Radiation Therapy Committee will define the criteria after publication of the results from the trial</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

